New York State Common Retirement Fund Decreases Position in Ascendis Pharma A/S (NASDAQ:ASND)

New York State Common Retirement Fund cut its position in Ascendis Pharma A/S (NASDAQ:ASND) by 0.1% in the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 204,548 shares of the biotechnology company’s stock after selling 152 shares during the period. New York State Common Retirement Fund’s holdings in Ascendis Pharma A/S were worth $25,763,000 as of its most recent SEC filing.

Other large investors have also bought and sold shares of the company. Handelsbanken Fonder AB increased its holdings in Ascendis Pharma A/S by 26.3% during the third quarter. Handelsbanken Fonder AB now owns 11,367 shares of the biotechnology company’s stock valued at $1,064,000 after buying an additional 2,367 shares during the last quarter. Harbor Capital Advisors Inc. boosted its position in shares of Ascendis Pharma A/S by 17.4% during the third quarter. Harbor Capital Advisors Inc. now owns 14,135 shares of the biotechnology company’s stock worth $1,324,000 after acquiring an additional 2,092 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its stake in Ascendis Pharma A/S by 53.6% during the third quarter. Raymond James Financial Services Advisors Inc. now owns 14,990 shares of the biotechnology company’s stock valued at $1,404,000 after purchasing an additional 5,229 shares in the last quarter. Brown Advisory Inc. raised its stake in Ascendis Pharma A/S by 2.7% during the third quarter. Brown Advisory Inc. now owns 510,109 shares of the biotechnology company’s stock valued at $47,767,000 after purchasing an additional 13,227 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its stake in Ascendis Pharma A/S by 7.1% during the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 13,803 shares of the biotechnology company’s stock valued at $1,293,000 after purchasing an additional 921 shares in the last quarter.

Wall Street Analyst Weigh In

Several brokerages have recently weighed in on ASND. Wedbush increased their target price on shares of Ascendis Pharma A/S from $207.00 to $225.00 and gave the company an “outperform” rating in a research note on Thursday, February 8th. Citigroup raised their price target on shares of Ascendis Pharma A/S from $146.00 to $182.00 and gave the stock a “buy” rating in a research note on Thursday, February 8th. Wells Fargo & Company increased their target price on shares of Ascendis Pharma A/S from $196.00 to $260.00 and gave the stock an “overweight” rating in a report on Friday, March 15th. Morgan Stanley reiterated an “equal weight” rating and issued a $116.00 target price on shares of Ascendis Pharma A/S in a research note on Monday, April 22nd. Finally, JPMorgan Chase & Co. lifted their target price on shares of Ascendis Pharma A/S from $165.00 to $167.00 and gave the stock an “overweight” rating in a research note on Tuesday, April 2nd. Two research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat, Ascendis Pharma A/S presently has a consensus rating of “Moderate Buy” and an average target price of $173.25.

Ascendis Pharma A/S Price Performance

NASDAQ:ASND opened at $135.90 on Friday. The firm has a market cap of $7.91 billion, a price-to-earnings ratio of -14.69 and a beta of 0.50. The company has a 50 day moving average price of $148.88 and a 200-day moving average price of $125.68. Ascendis Pharma A/S has a 1-year low of $66.03 and a 1-year high of $161.00.

Ascendis Pharma A/S (NASDAQ:ASND) last posted its earnings results on Wednesday, February 7th. The biotechnology company reported ($1.66) earnings per share for the quarter, beating the consensus estimate of ($2.15) by $0.49. Ascendis Pharma A/S had a negative net margin of 180.61% and a negative return on equity of 16,574.15%. The firm had revenue of $148.62 million during the quarter, compared to analyst estimates of $97.02 million. On average, sell-side analysts anticipate that Ascendis Pharma A/S will post -4.15 earnings per share for the current fiscal year.

Ascendis Pharma A/S Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.